Multi-center study about an early steroid withdrawal immunosuppression in kidney transplant patients receiving everolimus

Multi-center study about an early steroid withdrawal immunosuppression in kidney transplant patients receiving everolimus - An early steroid withdrawal immunosuppression in kidney transplant patients receiving everolimus

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017572

Enrollment

100

Registered

2015-05-14

Start date

2012-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplant recipients

Interventions

Everolimus intake, kidney transplantation, 3 years, Set trough level between 3 to 8 ng/ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Living related kidney transplant patients who is between 16 and 70 years old age. Who can make informed consent properly.

Exclusion criteria

Exclusion criteria: The patients who cannot make informed consent properly. Who is unable to visit hospitals on scheduled dates. Who is pregnant. Who has an allergy to everolimus.

Design outcomes

Primary

Measure	Time frame
The incidence rate of acute rejection, The rate of kidney graft survival, The rate of patients survival, and the successful rate of steroid withdrawal	—

Secondary

Measure	Time frame
The incidence rate of cytomegalovirus infection, kidney graft function (e.g. eGFR or serum creatinine), The rate of adverse events, and the rate of biopsy-proven chronic allograft nephropathy	—

Countries

Japan

Contacts

Public ContactMorita Shinya

Keio University School of Medicine Department of Urology

morishin75@yahoo.co.jp03-5363-3825

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026